Does hormone replacement therapy prevent cardiovascular disease among postmenopausal women?;L'hormonothérapie substitutive de la ménopause apporte-t-elle un bénéfice cardiovasculaire?

Revue de Medecine Interne

Volumn 24, Issue 4, 2003, Pages 216-217

  Scarabin, P Y ^a  

^a INSERM   (France)

Author keywords

Cardiovascular disease; Estrogen; Hormone replacement therapy; Menopause

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; THROMBIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; EDITORIAL; ESTROGEN THERAPY; HEART INFARCTION; HEART PROTECTION; HUMAN; LUNG EMBOLISM; META ANALYSIS; POSTMENOPAUSE; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 0038035363     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(02)00812-3     Document Type: Editorial

References (7)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA 2002;288:321-33.
2. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women, Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
3. The Coronary Drug Project, Initial findings leading to modifications of its research protocol. JAMA 1970;214:1303-13.
4. Caine YG, Bauer KA, Barzegar S. Coagulation activation following estrogen administration in postmenopausal women. Thromb Haemost 1992;68:392-5.
5. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women, A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-8.
6. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360: 942-4.
7. Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, et al. Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C among Postmenopausal Women: a Randomised Trial. Arterioscler Thromb Vasc Biol 2003 sous presse.